FIGS 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- FIGS reported Q3 2026 net revenues of $190.7 million, up 26% year over year, exceeding its approximately 20% outlook and marking its 4th consecutive quarter of greater than 25% growth.
- Active customers grew 14% year over year to nearly 3.2 million, average order value increased 11% to $126, and trailing 12-month net revenues per active customer rose 13% to a record $236.
- Scrubwear grew 24% and represented 83% of net revenues; non-scrubwear grew 35% and represented 17%. U.S. net revenues increased 21% to $153.9 million, and international net revenues increased 51% to $36.8 million.
- Gross margin was 69.3%, down 60 basis points year over year. Operating margin rose 520 basis points to 11.6%, and adjusted EBITDA margin rose 410 basis points to 16.5%. Net income was $19.3 million, or diluted EPS of $0.10.
- Cash, cash equivalents, and short-term investments totaled a record $331.2 million. Inventory decreased 20% year over year to $121.3 million, and FIGS repurchased approximately $14 million of shares during the quarter at a weighted average price of $14.02 per share.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
We will now hand the conference over to Tom Shaw, Senior Vice President of Investor Relations.
Please go ahead. Good afternoon, and thank you for joining us to discuss FIGS' third quarter 2026 results, which we released this afternoon and can be found in our earnings press release and in the shareholder presentation posted to our investor relations website at ir.wearFIGS.com.
Presenting on today's call are Trina Spear, our Co-Founder and Chief Executive Officer, and Sarah Oughtred, our Chief Financial Officer. As a reminder, remarks on this call that do not concern past events are forward-looking statements. These may include predictions, expectations, or estimates, including about future financial performance, market opportunity, or business plans. Forward-looking statements include risk and uncertainties, and actual results could differ materially. These and other risks are discussed in our SEC filings, including in the 10-Q we filed today. Do not place undue reliance on forward-looking statements, which speak only as of today, and which we undertake no obligation to update.
Finally, we will discuss certain non-GAAP metrics and key performance indicators, which we believe are useful supplemental measures for understanding our business. Definitions and reconciliations of these non-GAAP measures to their most comparable GAAP measures are included in our shareholder presentation. Now, I would like to turn the call over to Trina.
Thanks, Tom. Good afternoon, everyone, and thank you for joining us. FIGS delivered another remarkable quarter, exceeding expectations on both the top and bottom line. Net revenues grew 26% to approximately $191 million, well ahead of our 20% outlook and marking our fourth straight quarter of greater than 25% growth. Strength was once again broad-based across categories, channels, and geographies. Our customer data was highlighted by an acceleration in year-over-year growth across three key measures. This included active customer growth of 14% to nearly 3.2 million, average order value growth of 11% to $126, and net revenues per active customer growth of 13% to another FIGS record of $236. In addition to our top-line success, we also delivered increased profitability despite the elevated overall cost environment. Our adjusted EBITDA margin expanded to 16.5%, up 410 basis points year-over-year, surpassing our outlook of approximately 14%.
Gross margin remained incredibly strong at over 69%, and we saw greater than planned SG&A leverage, which again highlights the power of our model as we scale. We continue to put capital to work as we repurchased approximately $14 million of our shares during the period, following the additional $100 million buyback authorization announced in August. We have now delivered four amazing quarters in a row. Over this time, the consistent question we have received has been, how do we drive this sharp inflection in the business? The simple answer is that it has been through the combined efforts of great products, marketing campaigns that resonate deeply, a community that we are incredibly connected with, and strong industry fundamentals. But that simplicity understates the reality. Executing on all of this was not easy.
It required a step change across a range of areas where we had always been successful, but where we knew we had to get even better. At the heart of this work is the amazing team we have assembled over the past several years, with strong leaders and support fortifying our efforts across product, marketing, supply chain, finance, international teams, and Community Hubs. Their contributions and energy have been pivotal in unlocking this powerful story that has been there all along. On the product side, we have always had category-defining core offerings. What has changed is the sophistication we have added to every part of our go-to-market approach, which really began to take hold in the second half of 2025.
We are now more aligned than ever in how we understand and dictate style, deliver impactful color, improve fit, diversify our fabrics, enhance our merchandising, and invest in inventory across both core and limited edition. On the brand side, we renewed our focus on the top of the funnel, anchored by last year's "Where Do You Wear FIGS?" campaign and extending this year with "Never Change." We leveraged key viral moments from the Olympics to Noah Lyles at the Emmys, magnified our community support through expanded advocacy, and built greater sophistication across the full funnel. This collective impact is real and differentiated, and we have powered these efforts in product and brand to serve an industry that has become increasingly rare in today's landscape. In addition to the replenishment-driven and essential nature of healthcare apparel, the job backdrop is strong, with healthcare-related jobs powering the economy.
This is predicted to remain true going far into the future. Indeed, even amid fears of AI disruption, the Bureau of Labor Statistics projects the sector will add the most jobs over the next decade, about 37% of all new jobs. This is a fundamentally human profession, and we are proud to have built an authentic community around it. Just as we know this industry is incredibly strong, being successful depends on creating strong human connections to the healthcare professionals who power it. We have seen a number of longstanding players in the industry fall on hard times at the same time we have accelerated, and we believe it is our ability to drive product innovation, impact, and community connection that puts us on a different path. Even with this run of strong performance, we are focused on what is next, sustaining our momentum and driving growth over the long run.
Importantly, we see our recent efforts and success as foundational. They were never designed to simply be one-time wins, but rather sustainable building blocks that drive enduring impact for healthcare professionals. Great foundations enable further progress, and we are setting our sights across a multitude of opportunities to raise the high bar we have set again. For instance, in product, our enhanced design capabilities are just now starting to have a meaningful impact. Our inventory positioning and depth is set to improve and be optimized, and we are accelerating our head-to-toe category expansion, thereby creating TAM. As we think about our brand's reach, we are far from the finish line as we look to serve more of the 100 million plus global healthcare community. Domestically, we still have relatively low brand awareness, a digital experience that can become more personalized and engaging, and omnichannel connectivity that is untapped.
Internationally, we are still under 20% of our total mix, with a number of key growth markets still in early stages. Physical in-person access to our brand remains highly limited, with just nine Community Hubs open by the end of the year, and the TEAMS B2B opportunity to unlock institutional healthcare needs remains ahead of us. Additionally, on impact, our efforts to serve those who serve others are constant. This is a true brand differentiator and something our community deserves, and we are laser-focused on how we can scale this impact across our growing channels and geographies. Combining our momentum with these opportunities, we are optimistic about where we are going and how we can extend this unique growth story. Before diving deeper into product, brand, and market expansion, I want to update you on our supply chain following the Jordan developments we updated you on last quarter.
While the WRO is still in effect, our own efforts are progressing. Our team and I recently traveled to Southeast Asia, both to support our existing Vietnamese supplier relationships and to further our diversification efforts. We have secured additional capacity in Vietnam. Production is ramping, goods are being expedited, and inventory is improving real-time. In Q4, we are leveraging our existing partners to start our first production lines at facilities in Indonesia, which we expect will support a more meaningful mix of our business by the end of 2027. We are happy with our near-term progress, even as overall strength of demand extends some of our inventory replenishment efforts into Q1. Overall, this has been a complete team effort, particularly considering where our supplier base was positioned just 12 months ago. Now, let's turn to some of our product stories and where we are driving impact.
Our ongoing inflection in the business continues to showcase the growing sophistication in how we bring product and head-to-toe solutions to market. At the same time, our team is demonstrating the resilience needed to make impactful near-term changes to our calendar to mitigate supplier disruption. We delivered a range of impactful color collections throughout Q3, driving particular excitement on launch days. Success was broad-based and included our Spider-Man collaboration, back-to-school, a limited espresso drop, breast cancer awareness, and more. Our new durable FIBREx fabrication exceeded expectations, with highly positive social sentiment and customers specifically calling out our streetwear styling, our durable structured silhouette, and our overall design. Speaking of design, we continue to differentiate our scrub pant offering with new waistband solutions across several of our best-selling styles.
With our recent acquisition of V Coterie, we broadened our non-scrubwear opportunity with a dedicated collection of jewelry, pins, charms, and accessories designed specifically for healthcare professionals. This product officially debuted in August under what we are calling the CHARxMACY, creating a natural extension of the uniform by combining emotional engagement, personalization, and collectability. As we previously indicated, much of the original launch sold out, and we amassed a waiting list of nearly 10,000 healthcare professionals as we work to rebuild the assortment ahead of the holidays. For Q4, we are off to a fast start with our fall drop, featuring a full return of our most requested color, espresso. The launch also showcased our unparalleled innovation flywheel, where we brought new fabric and style as part of our boucle outerwear assortment.
Over the last few weeks, we have also started to get healthier from an inventory perspective, including in our core Rafaela and Kade styles, a process that will continue in the months ahead as we build supply and chase strong demand. We are excited to bring more newness across our FIBREx and FORMx fabrications, as well as our popular bag lines. The reach of our brand has never been broader or more impactful. Impact trips are always a hallmark of our efforts to change healthcare. Through these trips, we travel the world with our FIGS ambassadors to extend support across a diverse range of healthcare needs. In July, we partnered with Operation Walk Los Angeles and St. Elizabeth Hospital to send a team to the Philippines to provide over 40 free joint replacements.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
13 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
